- AuthorisedTherapeutic exploratory (Phase II)
A Long-term Multicenter Open-label Study to Evaluate the Long-term Safety and Durability of Effect of XTMAB-16 in Patients With Pulmonary Sarcoidosis With or Without Extra pulmonary Involvement
This study is looking at a new medicine, XTMAB-16, for people with sarcoidosis that affects their lungs, and sometimes other parts of their body. It wants to see if the medicine is safe over a long time and if it continues to work well.
For: Pulmonary sarcoidosis with or without extrapulmonary manifestationsCzechia · Denmark · Poland - Enrolling by invitationPHASE2
An Open-label Extension Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis
This study looks more closely at a new medicine called XTMAB-16 for people with lung sarcoidosis. It aims to see if the treatment remains safe and effective over a longer time, including for those whose sarcoidosis affects other parts of their body too.
For: Pulmonary SarcoidosisUnited States · Czechia · Poland